TY - JOUR
T1 - Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia
AU - Kim, Eun Ah
AU - Lim, Young Tae
AU - Hah, Jeong Ok
AU - Sohn, Young Bae
AU - Kim, Yu Kyung
AU - Choi, Joon Hyuk
AU - Kim, Sae Yoon
AU - Jang, Kyung Mi
AU - Ahn, Ji Young
AU - Lee, Jae Min
N1 - Publisher Copyright:
© 2018, The Japanese Society of Hematology.
PY - 2019/3/20
Y1 - 2019/3/20
N2 - Gaucher disease (GD) is caused by a hereditary deficiency of glucocerebrosidase, resulting in accumulation of glucosylceramide and potentially manifesting as hepatosplenomegaly. We report the case of a 15-month-old boy with chronic neuronopathic GD. The patient had prolonged anemia despite continued iron supplementation for 3 months. White blood count (WBC), hemoglobin (Hb), platelet count, and corrected reticulocyte count were 3,300 /µL, 8.7 g/dL, 90,000 /µL, and 0.55, respectively. The patient had microcytic hypochromic anemia with mildly elevated ferritin. Physical examination revealed hepatosplenomegaly. Bone-marrow aspiration showed sheets of Gaucher cells. Glucocerebrosidase activity in monocytes was significantly lower than normal. Genetic analysis revealed a homozygous L444P mutation of GBA, and he was diagnosed with type 1 GD. Enzyme replacement treatment (ERT) consisting of imiglucerase was initiated and was effective; WBC, Hb, and platelet count gradually normalized and the hepatosplenomegaly improved. However, when the patient entered elementary school, he showed mild impaired cognitive function, and supranuclear gaze palsy occurred the same year. He was ultimately diagnosed with type 3 GD and continued ERT. Pediatric hemato-oncologists should be aware of GD, especially when patients exhibit anemia refractory to iron therapy, radiologic bone deformity, neurologic signs or symptoms, and growth retardation.
AB - Gaucher disease (GD) is caused by a hereditary deficiency of glucocerebrosidase, resulting in accumulation of glucosylceramide and potentially manifesting as hepatosplenomegaly. We report the case of a 15-month-old boy with chronic neuronopathic GD. The patient had prolonged anemia despite continued iron supplementation for 3 months. White blood count (WBC), hemoglobin (Hb), platelet count, and corrected reticulocyte count were 3,300 /µL, 8.7 g/dL, 90,000 /µL, and 0.55, respectively. The patient had microcytic hypochromic anemia with mildly elevated ferritin. Physical examination revealed hepatosplenomegaly. Bone-marrow aspiration showed sheets of Gaucher cells. Glucocerebrosidase activity in monocytes was significantly lower than normal. Genetic analysis revealed a homozygous L444P mutation of GBA, and he was diagnosed with type 1 GD. Enzyme replacement treatment (ERT) consisting of imiglucerase was initiated and was effective; WBC, Hb, and platelet count gradually normalized and the hepatosplenomegaly improved. However, when the patient entered elementary school, he showed mild impaired cognitive function, and supranuclear gaze palsy occurred the same year. He was ultimately diagnosed with type 3 GD and continued ERT. Pediatric hemato-oncologists should be aware of GD, especially when patients exhibit anemia refractory to iron therapy, radiologic bone deformity, neurologic signs or symptoms, and growth retardation.
KW - Anemia
KW - Enzyme replacement treatment
KW - Gaucher disease
KW - Neuronopathic gaucher disease
UR - http://www.scopus.com/inward/record.url?scp=85056846175&partnerID=8YFLogxK
U2 - 10.1007/s12185-018-2559-3
DO - 10.1007/s12185-018-2559-3
M3 - Article
C2 - 30456712
AN - SCOPUS:85056846175
SN - 0925-5710
VL - 109
SP - 361
EP - 365
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 3
ER -